HC Wainwright Increases Korro Bio (NASDAQ:KRRO) Price Target to $115.00

Korro Bio (NASDAQ:KRRO) had its price objective upped by investment analysts at HC Wainwright from $100.00 to $115.00 in a report issued on Thursday, Marketbeat Ratings reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 29.90% from the stock’s previous close.

Several other analysts have also recently commented on KRRO. Piper Sandler restated an “overweight” rating and issued a $180.00 target price on shares of Korro Bio in a research note on Wednesday. Royal Bank of Canada lifted their price target on Korro Bio from $70.00 to $90.00 and gave the company an “outperform” rating in a research note on Wednesday. Finally, BMO Capital Markets restated an “outperform” rating and set a $120.00 target price on shares of Korro Bio in a research report on Tuesday.

Korro Bio Stock Up 1.8 %

Korro Bio stock opened at $88.53 on Thursday. The firm has a market cap of $65.51 million, a PE ratio of -0.94 and a beta of 2.09. The stock’s 50 day moving average is $54.43. Korro Bio has a twelve month low of $9.15 and a twelve month high of $97.91.

Hedge Funds Weigh In On Korro Bio

A number of hedge funds have recently made changes to their positions in the stock. North Star Investment Management Corp. acquired a new stake in Korro Bio during the fourth quarter worth about $48,000. Tower Research Capital LLC TRC acquired a new position in shares of Korro Bio during the 4th quarter valued at $190,000. Northern Trust Corp purchased a new stake in Korro Bio during the 4th quarter worth $504,000. Verition Fund Management LLC acquired a new stake in Korro Bio in the 4th quarter valued at $2,784,000. Finally, Monashee Investment Management LLC purchased a new stake in shares of Korro Bio in the fourth quarter worth about $4,352,000. Institutional investors and hedge funds own 13.18% of the company’s stock.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc is based in Cambridge, Massachusetts.